The entire universe is still wrestling with the new virus that is slowly wiping away mankind from the land of the living every passing minute.
19 cases have been recorded with 1 person confirmed dead and this has sent some shocks through the bone joints of Ghanaians as to how the country is going to face and prevent the spread of the deadly virus.
SEE ALSO:KNUST female Student electrocuted to death while taking her Shower.
Resent research on the Coronavirus pandemic has shown that individuals with blood group type A may be more prone and likely to die when infected by COVID-19 than others.
After critical analyses, over 2,000 COVID-19 patients in China’s epicentre of Wuhan, found out that those with blood group type A showed a higher rate of being infected, show more symptoms, and die more than other infected people with different blood group.
However, people with O type tended to experienced more mild symptoms from the disease and suffered fewer deaths.
Comparing the blood group types of these patients to those of over 3,600 unaffected people, the research shows that while 31.16 percent of regular residents were blood type A, 37.75 percent of surveyed coronavirus patients were of the same blood type.
SEE ALSO:Nothing can make me leave my husband – Actress Beverly Afaglo
Of the same sample of coronavirus cases at the hospital, 25.8 percent had type O blood, compared to 33.84 percent in the general population.
The study also examined 206 patients who lost their lives from the virus, finding 85 victims, or 41.26 percent, had Type A blood. Just 52 of the deaths, or about a quarter, had Type O.
“People of blood group A might need particularly strengthened personal protection to reduce the chance of infection.
“Sars-CoV-2-infected patients with blood group A might need to receive more vigilant surveillance and aggressive treatment.”
“…blood group O had a significantly lower risk for the infectious disease compared with non-O blood groups,” the research published on Medrxiv.org stated.
The researchers being led by Wang-Xinghuan of the Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, however, described their research as “preliminary” and have recommended further studies.
